Established in 1980 and based in Castellbisbal, near Barcelona (Spain), Inke combines over 20 years of in-house experience in micronization and particle engineering with complex synthesis processes and high regulatory expertise. It has established preferential relationships with major pharmaceutical companies worldwide, including in key markets such as the US and the EU, as well as the highly regulated Japanese market.
The firm previously advised Permira on its acquisition of Neuraxpharm in 2020. The Clifford Chance cross-border multidisciplinary team advising Neuraxpharm was led by M&A Private Equity partners Samir Azzouzi and Jörg Rhiel from the Madrid and Frankfurt offices, respectively, supported by senior associate Daniel García Juárez and associates Andreína Velásquez, Sofía Albiñana and Juan Valcárcel, from the M&A Private Equity practice in Madrid. Partner André Duminy and senior associate Claudia Hall from the London office also assisted with the transaction.
On the other hand, Garrigues advised Keensight Capital with a team comprising partner Laura Muñoz (pictured) and associates Elisabet Terradellas, Joana Sneyers, Sandra Velaz and Claudia García.
